{"id":"2014-alc-919-us","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Hypothyroidism"},{"rate":"1-2%","effect":"Hyperthyroidism"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"},{"rate":"5-10%","effect":"Arthralgia"},{"rate":"5-10%","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PD-1 receptor, the drug enhances the body's immune response to cancer cells, allowing for more effective treatment. This mechanism is based on the principle of immune checkpoint inhibition, which has shown promise in various cancer therapies.","oneSentence":"This drug targets the PD-1 receptor to modulate the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:25:50.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT02483455","phase":"PHASE2","title":"ALC-919 For The Treatment Of Common Warts","status":"COMPLETED","sponsor":"Veloce BioPharma LLC","startDate":"2015-04","conditions":"Verruca Vulgaris","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ALC-919"],"phase":"phase_2","status":"active","brandName":"2014-ALC-919-US","genericName":"2014-ALC-919-US","companyName":"Veloce BioPharma LLC","companyId":"veloce-biopharma-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The 2014-ALC-919-US study was a completed clinical trial that investigated the efficacy of a Vehicle-Control Topical Solution for the treatment of Verruca Vulgaris, also known as common warts. The study was conducted by Veloce BioPharma LLC and was completed in 2016.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}